U.S. FDA Opposes Otsuka suit, Apotex Can Challenge Benicar Patents
This article was originally published in PharmAsia News
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.
You may also be interested in...
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
Pitfalls of using third-party hubs for reimbursement assistance, sharing preapproval data with patient groups, and promoting biosimilars with labeling carveouts are among the concerns noted by panelists at FDLI conference.